EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2 ‐Positive Cancers

Yuya Murase iD, Shigeki Nanjo, Sachiko Arai, Sota Kondo, Hayato Koba, Yifeng Liu, Koji Fukuda iD, Shigeki Sato, Jun Kinoshita iD, Noriyuki Inaki, Tsukasa Ueda, Shunichi Nomura und 12 weitere

Cancer Science · 2026-04 · 117 (4) · 996-1009

DOI: 10.1111/cas.70319 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 17.01.2026. Verfasst von Yuya Murase und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Bliss Biopharmaceutical (Hangzhou) Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) are emerging as a promising class of targeted cancer therapy. Trastuzumab deruxtecan (T‐DXd), a human epidermal growth factor receptor 2 (HER2)‐directed ADC, has demonstrated clinical efficacy in HER2‐positive gastric and breast cancers, as well as in HER2‐mutant non‐small cell lung cancer. However, the development of acquired resistance limits their long‐term efficacy. To elucidate the resistance mechanism, we established T‐DXd‐resistant cell lines derived from HER2‐amplified gastric xenografts (N87 acquired resistance [AR]) and leptomeningeal carcinomatosis (Calu‐3 AR) lung cancer cells. N87 AR cells exhibited cross‐resistance to T‐DXd, payload DXd, and topoisomerase I inhibitor SN‐38 despite preserved HER2 expression and intact drug internalization. As payload resistance‐related molecules, ATP‐binding cassette (ABC) transporter ABCG2 and ABCB1 were markedly upregulated in N87 AR and Calu‐3 cells, respectively. Inhibition of ABCG2 and ABCB1 in N87 AR and Calu‐3 cells, respectively, through siRNA‐mediated knockdown restored T‐DXd sensitivity in both models. As a strategy to overcome resistance, pharmacological inhibitors of ABCG2 and ABCB1 restored the T‐DXd sensitivity of N87 AR and Calu‐3 cells, respectively. Moreover, BB‐1701, a novel HER2‐ADC containing eribulin as a payload, to which N87 AR cells are sensitive, exhibited antitumor effects in N87 AR cells in vitro and in vivo. These findings indicate that ABC transporter‐mediated drug efflux is an important mechanism underlying T‐DXd resistance in HER2‐positive gastric and lung cancer models. Furthermore, our study suggests that both targeting drug efflux pathways and utilizing alternative payloads may be effective strategies for overcoming T‐DXd resistance in HER2‐positive gastric and lung cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabCamptothecinStomach NeoplasmsLung NeoplasmsHumansAnimalsCell Line, TumorFemaleMiceXenograft Model Antitumor AssaysATP Binding Cassette Transporter, Subfamily G, Member 2Polyether PolyketidesATP Binding Cassette Transporter, Subfamily BNeoplasm ProteinsIrinotecan

Stichwörter der Autor:innen

ABC transportersBB‐1701HER2antibody–drug conjugatetrastuzumab deruxtecan

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabtrastuzumab deruxtecanCamptothecinERBB2 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2Polyether PolyketidesATP Binding Cassette Transporter, Subfamily BNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kanazawa, Ishikawa, Japan.
  • Division of Nano Life Science, Graduate School of Frontier Science Initiative, Kanazawa University, Kanazawa, Ishikawa, Japan.
  • Department of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.
  • Department of Gastrointestinal Surgery, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • Department of Molecular and Cellular Pathology, Kanazawa University, Kanazawa, Ishikawa, Japan.

ORCID-Profile: Yuya Murase, Koji Fukuda, Jun Kinoshita, Masafumi Horie, Seiji Yano

Förderung

  • Japan Society for the Promotion of Science
  • Bliss Biopharmaceutical (Hangzhou) Co. Ltd

Zitieren

APA

Murase, Y., Nanjo, S., Arai, S., Kondo, S., Koba, H., Liu, Y., Fukuda, K., Sato, S., Kinoshita, J., Inaki, N., Ueda, T., Nomura, S., Tambo, Y., Shimizu, T., Horie, M., Maeda, D., Wong, R. W., Hosomichi, K., Kobayashi, T., …, & Yano, S. (2026). Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2 ‐Positive Cancers. Cancer Science, 117(4), 996-1009. https://doi.org/10.1111/cas.70319

Vancouver

Murase Y, Nanjo S, Arai S, Kondo S, Koba H, Liu Y, et al. Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2 ‐Positive Cancers. Cancer Science. 2026;117(4):996-1009. doi:10.1111/cas.70319

BibTeX
@article{Murase2026,
  author = {Murase, Yuya and Nanjo, Shigeki and Arai, Sachiko and Kondo, Sota and Koba, Hayato and Liu, Yifeng and Fukuda, Koji and Sato, Shigeki and Kinoshita, Jun and Inaki, Noriyuki and Ueda, Tsukasa and Nomura, Shunichi and Tambo, Yuichi and Shimizu, Takahiro and Horie, Masafumi and Maeda, Daichi and Wong, Richard W and Hosomichi, Kazuyoshi and Kobayashi, Takafumi and Watanabe, Satoshi and Yamamura, Kenta and Ohkura, Noriyuki and Abo, Miki and Yano, Seiji},
  title = {Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2 ‐Positive Cancers},
  journal = {Cancer Science},
  year = {2026},
  volume = {117},
  number = {4},
  pages = {996--1009},
  doi = {10.1111/cas.70319}
}
Kostenlos starten →